Supernus Pharmaceuticals (SUPN) Stock Analysis & Winston Score

Supernus Pharmaceuticals is a specialty drug company that focuses on treatments for diseases of the central nervous system (CNS) — basically conditions affecting the brain and nervous system. Its main products include Qelbree (for ADHD), Oxtellar XR and Trokendi XR (both for epilepsy), and APOKYN and other drugs acquired from US WorldMeds for Parkinson's disease. Its customers are primarily neurologists and psychiatrists in the United States. The company earns money by selling branded prescription drugs directly to pharmacies and specialty distributors, who then supply patients. Supernus operates almost entirely in the U.S. market and generates strong gross margins above 80%, which is typical for branded specialty pharmaceuticals. However, its negative operating margin reflects heavy spending on research and development for pipeline drugs. The key growth driver is expanding Qelbree's market share in the competitive ADHD space, while the main risk is patent expiration on older products like Trokendi XR, which already faces generic competition that has pressured revenues.